A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia

OBJECTIVE: To explore the role of chidamide, decitabine plus priming regimen in the salvage treatment of relapsed/refractory acute myeloid leukemia. METHODS: A clinical trial was conducted in relapsed/refractory acute myeloid leukemia patients using chidamide, decitabine, cytarabine, idarubicin, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Jia, Wan, Chao-Ling, Zhang, Ling, Zhang, Hao, Bai, Lian, Zhou, Hai-Xia, Xu, Ming-Zhu, Chen, Li-Yun, Qian, Chong-Sheng, Qiu, Hui-Ying, Chen, Su-Ning, Tang, Xiao-Wen, Wu, De-Pei, Zhang, Yan-Ming, Sun, Ai-Ning, Xue, Sheng-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446637/
https://www.ncbi.nlm.nih.gov/pubmed/34540696
http://dx.doi.org/10.3389/fonc.2021.726926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446637/
https://www.ncbi.nlm.nih.gov/pubmed/34540696
http://dx.doi.org/10.3389/fonc.2021.726926

Ejemplares similares